MICHELLE LACOUTURE: Open Payments
NPI 1508507237 · DAVENPORT, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,342 in 59 payments from 14 companies in 2025. Trend: 2023 $459 · 2024 $900 · 2025 $1,342
Food & beverage: $1,313Education: $29
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $284 |
| Axsome Therapeutics, Inc. | 4 | $187 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $171 |
| Otsuka America Pharmaceutical, Inc. | 11 | $161 |
| Janssen Pharmaceuticals, Inc | 2 | $144 |
| Teva Pharmaceuticals USA, Inc. | 4 | $140 |
| Neurocrine BioSciences, Inc. | 2 | $110 |
| Lundbeck LLC | 2 | $30 |
| Corium, LLC | 1 | $26 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
Products named: VRAYLAR, Auvelity, CAPLYTA, SPRAVATO, REXULTI, AUSTEDO XR, INGREZZA, ABILIFY ASIMTUFII.
Industry payments across IA — which companies pay providers there.
